Mouse Anti-Human Cav3.2 (Clone N55/10) Monoclonal IgG1 Antibody
Cav3.2, encoded by the CACNA1H gene, is a low-voltage-activated T-type calcium channel that plays a critical role in regulating neuronal excitability, rhythmic firing, and calcium homeostasis. It is widely expressed in the brain and peripheral tissues, where it contributes to burst firing in thalamic neurons and modulates sensory signal transmission.
Genetic studies have linked mutations in CACNA1H to childhood absence epilepsy, highlighting Cav3.2’s role in thalamocortical oscillations and seizure susceptibility. Beyond epilepsy, dysregulation of Cav3.2 expression and function has been associated with broader neurological and neurodegenerative conditions, including neuropathic pain, Parkinson’s disease, and Alzheimer’s disease. Its involvement in calcium dysregulation—a hallmark of neurodegeneration—positions Cav3.2 as a potential therapeutic target for modulating neuronal survival and excitability.
Interestingly, Cav3.2 is also implicated in non-neuronal pathologies, such as prostate cancer progression, where its upregulation may support androgen-independent tumor growth. This underscores the channel’s broader physiological relevance and potential as a drug target across multiple disease domains.
Despite its clinical significance, many aspects of Cav3.2’s in vivo function, regulatory mechanisms, and disease-specific roles remain under investigation. Advancing our understanding of Cav3.2 could open new avenues for targeted therapies in epilepsy, neurodegeneration, and beyond.
This Mouse Anti-Human Cav3.2 (Clone N55/10) Monoclonal IgG1 Antibody is manufactured in Canada by StressMarq.
